These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30655764)

  • 1. Gadofosveset-enhanced MRI as simple surrogate parameter for real-time evaluation of the initial tumour vessel infarction by retargeted tissue factor tTF-NGR.
    Höink A; Persigehl T; Kwiecien R; Balthasar M; Mesters R; Berdel W; Heindel W; Bremer C; Schwöppe C
    Oncol Lett; 2019 Jan; 17(1):270-280. PubMed ID: 30655764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging.
    Persigehl T; Ring J; Bremer C; Heindel W; Holtmeier R; Stypmann J; Claesener M; Hermann S; Schäfers M; Zerbst C; Schliemann C; Mesters RM; Berdel WE; Schwöppe C
    Angiogenesis; 2014 Jan; 17(1):235-46. PubMed ID: 24136410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor.
    Brand C; Dencks S; Schmitz G; Mühlmeister M; Stypmann J; Ross R; Hintelmann H; Schliemann C; Müller-Tidow C; Mesters RM; Berdel WE; Schwöppe C
    J Ultrasound Med; 2015 Jul; 34(7):1227-36. PubMed ID: 26112625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile.
    Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE
    Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience.
    Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE
    Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
    Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
    Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study.
    Schliemann C; Gerwing M; Heinzow H; Harrach S; Schwöppe C; Wildgruber M; Hansmeier AA; Angenendt L; Berdel AF; Stalmann U; Berning B; Kratz-Albers K; Middelberg-Bisping K; Wiebe S; Albring J; Wilms C; Hartmann W; Wardelmann E; Krähling T; Heindel W; Gerss J; Bormann E; Schmidt H; Lenz G; Kessler T; Mesters RM; Berdel WE
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32517329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR.
    Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C
    Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation synergizes with antitumor activity of CD13-targeted tissue factor in a HT1080 xenograft model of human soft tissue sarcoma.
    Brand C; Greve B; Bölling T; Eich HT; Willich N; Harrach S; Hintelmann H; Lenz G; Mesters RM; Kessler T; Schliemann C; Berdel WE; Schwöppe C
    PLoS One; 2020; 15(2):e0229271. PubMed ID: 32084238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease.
    Gerwing M; Krähling T; Schliemann C; Harrach S; Schwöppe C; Berdel AF; Klein S; Hartmann W; Wardelmann E; Heindel WL; Lenz G; Berdel WE; Wildgruber M
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34884988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction.
    Berdel AF; Schwöppe C; Brand C; Harrach S; Brömmel K; Hintelmann H; Lenz G; Liersch R; Heinzow H; Schliemann C; Mesters RM; Berdel WE; Kessler T
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor.
    Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C
    Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic impact of CD13 expression in non-small cell lung cancer.
    Schmidt LH; Brand C; Stucke-Ring J; Schliemann C; Kessler T; Harrach S; Mohr M; Görlich D; Marra A; Hillejan L; Müller-Tidow C; Lenz G; Wardelmann E; Wiewrodt R; Berdel WE; Schwöppe C; Hartmann W
    PLoS One; 2017; 12(6):e0177146. PubMed ID: 28604784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
    Gregorc V; Citterio G; Vitali G; Spreafico A; Scifo P; Borri A; Donadoni G; Rossoni G; Corti A; Caligaris-Cappio F; Del Maschio A; Esposito A; De Cobelli F; Dell'Acqua F; Troysi A; Bruzzi P; Lambiase A; Bordignon C
    Eur J Cancer; 2010 Jan; 46(1):198-206. PubMed ID: 19900802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.
    Schmidt LH; Stucke-Ring J; Brand C; Schliemann C; Harrach S; Muley T; Herpel E; Kessler T; Mohr M; Görlich D; Kreuter M; Lenz G; Wardelmann E; Thomas M; Berdel WE; Schwöppe C; Hartmann W
    Lung Cancer; 2017 Nov; 113():121-127. PubMed ID: 29110838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-factor fusion proteins induce occlusion of tumor vessels.
    Schwöppe C; Kessler T; Persigehl T; Liersch R; Hintelmann H; Dreischalück J; Ring J; Bremer C; Heindel W; Mesters RM; Berdel WE
    Thromb Res; 2010 Apr; 125 Suppl 2():S143-50. PubMed ID: 20433995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor.
    Schwöppe C; Zerbst C; Fröhlich M; Schliemann C; Kessler T; Liersch R; Overkamp L; Holtmeier R; Stypmann J; Dreiling A; König S; Höltke C; Lücke M; Müller-Tidow C; Mesters RM; Berdel WE
    J Med Chem; 2013 Mar; 56(6):2337-47. PubMed ID: 23496322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
    Desar IM; van Herpen CM; van Asten JJ; Fiedler W; Marreaud S; Timmer-Bonte JN; ter Voert EG; Lambiase A; Bordignon C; Heerschap A; van Laarhoven HW
    Eur J Radiol; 2011 Dec; 80(3):655-61. PubMed ID: 20863638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.
    Di Matteo P; Hackl C; Jedeszko C; Valentinis B; Bordignon C; Traversari C; Kerbel RS; Rizzardi GP
    Br J Cancer; 2013 Jul; 109(2):360-9. PubMed ID: 23828516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadofosveset: MS 325, MS 32520, Vasovist, ZK 236018.
    Drugs R D; 2004; 5(6):339-42. PubMed ID: 15563237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.